Filing Flows

Filing Flows › Companies › Nutra Pharma › Cash flow

Nutra Pharma cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$251K in Q2 2026 · −$1.0M over twelve months

Operating cash flow−$251K
Free cash flow−$251K

Analysis

In Q2 2026, Nutra Pharma generated −$251K of operating cash flow. That is $37K more than in Q2 2025 (−$288K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$1.0M; the largest uses were operating cash flow ($1.0M); besides operations, cash came from net borrowing (+) / repaid (−) ($655K), other financing ($315K); the cash balance fell by $79K.

Operating cash flow was −$251K against net income of −$3.9M. The largest differences: accrued liabilities +$82K, payables +$45K, prepaid and other assets +$11K.

Free cash flow

Nutra Pharma: free cash flow by quarterNutra Pharma: free cash flow by quarter$19KQ3 2024−$178KQ4 2024−$431KQ1 2025−$288KQ2 2025−$251KQ3 2025−$220KQ4 2025−$328KQ1 2026−$251KQ2 2026
Operating cash flow less capital spending.
Nutra Pharma: operating cash flow against capital spendingNutra Pharma: operating cash flow against capital spendingOperating cash flowCapital spending$19K$0Q3 2024−$178K$0Q4 2024−$405K$26KQ1 2025−$288K$0Q2 2025−$251K$0Q3 2025−$220K$0Q4 2025−$328K$0Q1 2026−$251K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$251K, Capital spending $0.

Capital allocation, year by year

Nutra Pharma: where the cash came from (up) and went (down), by fiscal yearNutra Pharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingAsset salesCapital spendingFY2021: Operating cash flow −$1.7MFY2021: Net borrowing $2.2MFY2021: Capital spending −$39K$2.2MFY2021FY2022: Operating cash flow −$762KFY2022: Net borrowing $645KFY2022: Capital spending −$58K$645KFY2022FY2023: Operating cash flow −$550KFY2023: Net borrowing $81KFY2023: Asset sales $84K$164KFY2023FY2024: Operating cash flow −$424KFY2024: Net borrowing $183K$183KFY2024FY2025: Operating cash flow −$1.2MFY2025: Net borrowing $1.0MFY2025: Capital spending −$26K$1.0MFY2025
Over these 5 years operating cash flow totalled −$4.6M; the largest uses were operating cash flow ($4.6M) and capital spending ($123K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$39K
Debt$12.6M
Net debt$12.5M
Due within a year$8.5M
Cash runway0 months

Nutra Pharma is burning cash: its operations consume cash, a free cash flow of −$1.0M a year at the current rate against $39K of cash and investments: a runway of about 0 months; $8.5M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Nutra Pharma: debt maturities by year (FY2024)Nutra Pharma: debt maturities by year (FY2024)$8.5MYear 1$4KYear 2$4KYear 3$4KYear 4$4KYear 5$125KAfter year 5
Principal due in each year as disclosed in the annual report, against $39K of cash and investments now.

Where the cash came from and went

Nutra Pharma: sources (+) and uses (−) of cash, Q2 2026Nutra Pharma: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$251KNet borrowing (+) / repaid (−)$205KOther financing$24KCash drawn (+) / kept (−)$22K
Nutra Pharma: sources (+) and uses (−) of cash, TTM to Q2 2026Nutra Pharma: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$1.0MNet borrowing (+) / repaid (−)$655KOther financing$315KCash drawn (+) / kept (−)$79K

From profit to cash

Nutra Pharma: net income to operating cash flow, Q2 2026Nutra Pharma: net income to operating cash flow, Q2 2026Net income−$3.9MDepreciation & amortization$2KStock-based pay$4KReceivables−$109Inventory$3KPayables$45KAccrued liabilities$82KPrepaid and other assets$11KOperating cash flow−$251K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$251K—$205K$22K−$251K
Q1 2026−$328K—$220K−$10K−$328K
Q4 2025−$220K—$202K−$9K−$220K
Q3 2025−$251K—$28K$75K−$251K
Q2 2025−$288K—$379K−$65K−$288K
Q1 2025−$405K−$26K$403K$23K−$431K
Q4 2024−$178K—$34K−$36K−$178K
Q3 2024$19K—−$15K—$19K

Nutra Pharma: income statement and cash flow

Nutra Pharma, Q2 2026: revenue $34K (-59% year over year). The chart follows the revenue to costs, profit and cash.

Nutra Pharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.